Status:

COMPLETED

Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium

Lead Sponsor:

University of Colorado, Denver

Conditions:

Colistin

Eligibility:

All Genders

18-89 years

Brief Summary

Colistin is a polymixin antibiotic used in the treatment of multidrug-resistant gram-negative infections. Given the limited use of colistin and previous challenges with laboratory assays to determine ...

Detailed Description

Colistin, also known as polymixin E, is a peptide antibiotic that demonstrates concentration-dependent bactericidal killing against gram-negative pathogens including Pseudomonas and Acinetobacter. Ori...

Eligibility Criteria

Inclusion

  • Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection
  • Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)

Exclusion

  • Pregnancy
  • Breastfeeding
  • Prisoners

Key Trial Info

Start Date :

September 1 2013

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2019

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT02288429

Start Date

September 1 2013

End Date

June 1 2019

Last Update

June 24 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Colorado Hospital

Aurora, California, United States, 80045